AstraZeneca

9M and Q3 2024 Results

Conference call and webcast for investors and analysts

12 November 2024



Forward-looking statements

In order, among other things, to utilise the 'safe harbour' provisions of the US Private Securities Litigation Reform Act of 1995, AstraZeneca (hereafter 'the Group') provides the following cautionary statement: This document contains certain forward-looking statements with respect to the operations, performance and financial condition of the Group, including, among other things, statements about expected revenues, margins, earnings per share or other financial or other measures. Although the Group believes its expectations are based on reasonable assumptions, any forward-looking statements, by their very nature, involve risks and uncertainties and may be influenced by factors that could cause actual outcomes and results to be materially different from those predicted. The forward-looking statements reflect knowledge and information available at the date of preparation of this document and the Group undertakes no obligation to update these forward-looking statements. The Group identifies the forward-looking statements by using the words 'anticipates', 'believes', 'expects', 'intends' and similar expressions in such statements. Important factors that could cause actual results to differ materially from those contained in forward-looking statements, certain of which are beyond the Group's control, include, among other things: the risk of failure or delay in delivery of pipeline or launch of new medicines; the risk of failure to meet regulatory or ethical requirements for medicine development or approval; the risk of failures or delays in the quality or execution of the Group's commercial strategies; the risk of pricing, affordability, access and competitive pressures; the risk of failure to maintain supply of compliant, quality medicines; the risk of illegal trade in the Group's medicines; the impact of reliance on third-party goods and services; the risk of failure in information technology or cybersecurity; the risk of failure of critical processes; the risk of failure to collect and manage data in line with legal and regulatory requirements and strategic objectives; the risk of failure to attract, develop, engage and retain a diverse, talented and capable workforce; the risk of failure to meet regulatory or ethical expectations on environmental impact, including climate change; the risk of the safety and efficacy of marketed medicines being questioned; the risk of adverse outcome of litigation and/or governmental investigations; intellectual property related risks to the Group's products; the risk of failure to achieve strategic plans or meet targets or expectations; the risk of failure in financial control or the occurrence of fraud; the risk of unexpected deterioration in the Group's financial position; the impact that global and/or geopolitical events may have or continue to have on these risks, on the Group's ability to continue to mitigate these risks, and on the Group's operations, financial results or financial condition. Nothing in this document, or any related presentation/webcast, should be construed as a profit forecast.

9M and Q3 2024 Results

Conference call agenda

CEO Opening Remarks	**Pascal Soriot** Chief Executive Officer	
Financial Results	**Aradhana Sarin** Chief Financial Officer	
Oncology	**Dave Fredrickson** EVP, Oncology Business	**Susan Galbraith** EVP, Oncology R&D
BioPharmaceuticals	**Ruud Dobber** EVP, BioPharmaceuticals Business	**Sharon Barr** EVP, BioPharmaceuticals R&D
Rare Disease	**Marc Dunoyer** Chief Executive Officer, Alexion	
CEO Closing Remarks, Q&A	**Pascal Soriot** Chief Executive Officer	



CEO Opening Remarks

Pascal Soriot
CHIEF EXECUTIVE OFFICER



Strong underlying performance in Q3 and 9M 2024

Double-digit Total Revenue and Core EPS growth

Q3 and 9M 2024 vs prior year

	Q3 2024	9M 2024
Total Revenue	+21%	+19%
Core EPS	+27%	+11%

Double-digit growth across focus therapy areas

9M 2024 vs prior year



Upgraded FY2024 Guidance – Total Revenue and Core EPS expected to increase by high teens percentage

Appendix: Glossary.

Benefitting from global presence of growing portfolio

Double-digit growth across US, EU and EM with broad-based distribution of Total Revenue



ERoW = Established Rest of World comprises Japan, Canada, Australia, and New Zealand.
Appendix: Glossary.

Multiple high-value Phase III readouts in 2024

LAURA | Stg III u/r NSCLC

Expanding *Tagrisso* as backbone TKI in early-stage NSCLC

ECHO | MCL

Calquence first BTKi to show favourable overall survival trend

AMPLIFY | CLL

Securing *Calquence* leadership with finite treatment option

DESTINY-Breast06 | mBC

Enhertu moving into CTx naïve mBC, benefit in HER2-ultralow

ADRIATIC | LS-SCLC

Imfinzi first and only IO to show survival benefit in LS-SCLC

NIAGARA | MIBC

Imfinzi first perioperative IO regimen to extend survival in muscle-invasive bladder cancer

WAYPOINT | CRwNP

Tezspire first TSLP mAb to show benefit in nasal polyps

KOMET | adult NF1-PN

Koselugo extends strong clinical benefit to adult patient population with high unmet need

Indication expansion opportunities above represent combined PYR >$5bn[1]

1. Total non-risk adjusted Peak Year Revenue estimate for the eight trials shown on this slide.
Collaboration partners: Daiichi Sankyo (*Enhertu*); Amgen (*Tezspire*); Merck & Co., Inc. (*Koselugo*).
Appendix: Glossary.

Financial Results

Aradhana Sarin
CHIEF FINANCIAL OFFICER



Global demand growth across leading medicines

Top medicines by 9M 2024 Total Revenue

	Total Revenue $ million	Growth vs. PY CER%
Farxiga	5,779	34%
Tagrisso	4,877	15%
Imfinzi	3,463	22%
Ultomiris	2,835	35%
Calquence	2,321	27%
Lynparza	2,228	10%
Symbicort	2,195	22%
Soliris	2,045	(11%)
Enhertu	1,442	60%
Fasenra	1,218	8%
Strensiq	996	19%

Strong Product Sales and Alliance Revenue momentum through 9M 2024

Collaboration partners: Daiichi Sankyo (*Enhertu*); Merck & Co., Inc. (*Lynparza*).
Appendix: Glossary.

9M and Q3 2024 – Reported profit and loss



	9M 2024 $m	CER change %	% Total Revenue	Q3 2024 $m	CER change %	% Total Revenue
Total Revenue	**39,182**	**19**	**100**	**13,565**	**21**	**100**
- Product Sales	*37,576*	*19*	*96*	12,947	*20*	*95*
- Alliance Revenue	*1,498*	*50*	*4*	559	*50*	*4*
- Collaboration Revenue	*108*	*(66)*	-	59	*(40)*	-
Product Sales Gross Margin[1]	80.1%	-1pp		76.2%	-4pp	
Total operating expense[2]	(23,885)	9	61	(8,403)	13	62
- R&D expense	(8,906)	14	23	(3,115)	21	23
- SG&A expense	(14,567)	7	37	(5,143)	8	38
Other operating income and expense	152	(88)	-	25	(61)	-
Operating profit	7,967	23	20	2,106	18	16
Tax rate	21%			22%		
Reported EPS	**$3.57**	**21**		**$0.92**	**17**	

Due to rounding, the sum of a number of dollar values and percentages may not agree to totals. Absolute values at actual exchange rates; changes at CER.
1. Product Sales Gross Margin excludes the impact of Alliance and Collaboration Revenue and any associated costs, thereby reflecting the underlying performance of Product Sales. 2. Total operating expense includes distribution, R&D and SG&A expenses.
Appendix: Glossary.

9M and Q3 2024 – Core profit and loss



	9M 2024 $m	CER change %	% Total Revenue	Q3 2024 $m	CER change %	% Total Revenue
Total Revenue	**39,182**	**19**	**100**	**13,565**	**21**	**100**
- Product Sales	*37,576*	*19*	*96*	12,947	*20*	*95*
- Alliance Revenue	*1,498*	*50*	*4*	559	*50*	*4*
- Collaboration Revenue	*108*	*(66)*	-	59	*(40)*	-
Product Sales Gross Margin[1]	81.9%	-		81.1%	-	
Total operating expense[2]	(19,803)	15	51	(6,818)	16	50
- R&D expense	(8,638)	18	22	(3,068)	24	23
- SG&A expense	(10,753)	13	27	(3,605)	9	27
Other operating income and expense	149	(87)	-	24	(61)	-
Operating profit	12,729	13	32	4,318	27	32
Tax rate	20%			19%		
Core EPS	**$6.12**	**11**		**$2.08**	**27**	

Due to rounding, the sum of a number of dollar values and percentages may not agree to totals. Absolute values at actual exchange rates; changes at CER.
1. Product Sales Gross Margin excludes the impact of Alliance and Collaboration Revenue and any associated costs, thereby reflecting the underlying performance of Product Sales. 2. Total operating expense includes distribution, R&D and SG&A expenses.
Appendix: Glossary.

Upgrading FY 2024 guidance

Net cash inflow from operating activities increased 12% in 9M 2024

Net debt bridge



FY 2024 guidance upgraded (CER)

Given strong performance and increased confidence in achieving certain sales milestones, FY guidance is upgraded:

- **Total Revenue** anticipated to increase by a high teens percentage
- **Core EPS** anticipated to increase by a high teens percentage
  - Other elements of the Income Statement are expected to be broadly in-line with the indications issued in the Company's H1 2024 earnings statement

Net debt/Adjusted EBITDA 1.8x

Anticipated FX impact: low single-digit adverse impact on Total Revenue and mid single-digit impact on Core EPS[3]

Due to rounding, the sum of a number of dollar values and percentages may not agree to totals. 1. Comprises purchase and disposal of intangible assets, movement in profit participation liability, purchase and disposal of non-current asset investments, payments to associates and joint ventures, disposal of investments in associates and joint ventures, acquisitions of subsidiaries, net of acquired net debt, payment of contingent consideration on business combinations and payment ofAcerta Pharma share purchase liability. The Company uses Debt issuance to finance new Business Development opportunities. 2. Rolling 12m EBITDA adding back the impact of unwind of inventory fair value uplift recognised on acquisition of Alexion of $36m (FY 2023: $114m). AstraZeneca credit ratings: Moody's: short-term rating P-1, long-term rating A2, outlook positive. S&P Global Ratings: short-term rating A-1, long-term rating A+, outlook stable. 3. If foreign exchange rates for October to December were to remain at the average rates seen in September 2024. Appendix: Glossary.

Oncology

Dave Fredrickson
ONCOLOGY BUSINESS

Susan Galbraith
ONCOLOGY R&D



Oncology – 9M and Q3 2024

Total Revenue +22% in 9M 2024 driven by global demand for key medicines

Oncology

9M 2024 $16.0bn, +22%



Q3 2024: key dynamics

- ***Tagrisso*** +17%, strong demand across indications and lengthening DoT
- ***Calquence*** +25%, sustained BTKi leadership in 1L CLL
- ***Imfinzi*** +16%, demand growth in US and EU, continued JP repricing impact
- ***Imjudo*** +22%, demand from HCC (HIMALAYA) in US, NSCLC (POSEIDON) in EU
- ***Lynparza* PS** +13%, sustained PARPi leadership, driven by US and EU
- ***Enhertu*** +55%, established SoC in HER2+ (DB03) and HER2-low (DB04), encouraging early adoption in tumour agnostic
- ***Truqap*** n/m, new market leader in 2L biomarker-altered population

- New indications: US (*Imfinzi* AEGEAN, *Tagrisso* LAURA), EU (*Imfinzi* and *Lynparza* DUO-E), CN (*Enhertu* HER2+ gastric and *HER2*m NSCLC)
- Other regulatory: US Priority Review (*Calquence* ECHO, *Enhertu* DB06, *Imfinzi* ADRIATIC)

All growth rates at CER.
Collaboration partners: Daiichi Sankyo (*Enhertu*); Merck & Co., Inc. (*Lynparza*).
Appendix: Glossary.

Oncology – R&D highlights

Continuing momentum across Oncology with data at key medical congresses in H2 2024

WCLC and ESMO 2024

Expanding into bladder cancer and advancing next-gen IO and ADCs

NIAGARA
muscle invasive bladder cancer

- only perioperative IO regimen to show OS benefit
- potential new SoC

~120k MIBC patients (G8)

VOLGA (cis-ineligible MIBC) | Phase III readout H2 2025

Next-wave IO bispecifics — **In-house ADCs** — **Novel QCS biomarker**

Advancing haematology with upcoming data at ASH 2024

AMPLIFY
fixed duration *Calquence* in 1L CLL

- clinically meaningful PFS improvement
- trend to OS benefit

AZD0486
CD19/CD3 TCE

- high CR rate in r/r DLBCL
- high levels of complete remission in r/r FL
- good tolerability

Collaboration partner: Daiichi Sankyo (Dato-DXd).
Appendix: Glossary.

Oncology – R&D highlights

Reinforcing leadership in *EGFR*m NSCLC with novel treatment approaches

Tagrisso established backbone treatment for *EGFR*m NSCLC

Early-stage

- ADAURA
- LAURA
- NeoADAURA (trial ongoing)
- ADAURA2 (trial ongoing)

1st-line

- FLAURA
- FLAURA2

2nd-line+

- AURA1-3

established SoC | trial ongoing

Novel combinations extend *Tagrisso* use across multiple lines of therapy

SAVANNAH
- high and durable response rate
- well tolerated

SAFFRON
- confirmatory Phase III
- readout H2 2025

Convenient all oral regimen

TROPION-Lung05 — Phase II | 2023 readout
44% ORR, 5.8m mPFS

TROPION-Lung14 — 1L NSCLC | >2025

TROPION-Lung15 — 2L NSCLC | >2025

Dato-DXd | FDA submission *EGFR*m later line NSCLC | TROPION-Lung01 withdrawn

Tagrisso + savolitinib | 2L
34% in SAVANNAH were high MET expressing[1]

Tagrisso + Dato-DXd | 1L and 2L+
Potential to replace systemic chemotherapy

1. Defined as IHC90+ and/or FISH10+.
Collaboration partners: Daiichi Sankyo (Dato-DXd); Hutchmed (*Orpathys*).
Appendix: Glossary.

BioPharmaceuticals

Ruud Dobber
BIOPHARMACEUTICALS BUSINESS

Sharon Barr
BIOPHARMACEUTICALS R&D



BioPharmaceuticals – 9M and Q3 2024

Total Revenue $15.9bn, +20% – strong growth across CVRM, R&I and V&I

CVRM

9M 2024 $9.4bn, +21%



R&I

9M 2024 $5.8bn, +24%



Q3 2024: key dynamics

- ***Farxiga*** +27%, strong global demand growth
- ***Wainua*** n/m**,** accelerated new patient starts
- ***Breztri*** +57%, share gains in triple FDC class
- ***Tezspire*** >2x, continued growth in US, increasing new patient share EU, JP and EM
- ***Airsupra*** n/m**,** strong launch momentum
- ***Symbicort*** +31%, continued demand growth
- **V&I** +49%:
  - ***Beyfortus*** +72%, production capacity expanded to meet strong demand
  - ***FluMist*** +31%, seasonal demand growth

All growth rates at CER.
Collaboration partners: Amgen (*Tezspire*); Sanofi (*Beyfortus*); Ionis (*Wainua*).
Appendix: Glossary.

BioPharmaceuticals – R&D highlights

Multiple high potential NMEs and novel combinations to drive next wave of CVRM growth

	Cardiovascular heart failure | hypertension | dyslipidaemia | ATTR-CM	Renal chronic kidney disease	Metabolism T2D | weight mgmt.
	***Farxiga* (oSGLT2i) | foundational medicine in T2D, HF and CKD**		
monotherapy	**baxdrostat (ASI)** | Phase III		**AZD5004 (oGLP1)** | Phase IIb
monotherapy	***Wainua* (TTR ASO)** | Phase III **ALXN2220 (anti-ATTR mAb)** | Phase III		**AZD6234 (LAA)** | Phase IIb
monotherapy	**AZD5462 (oRXFP1)** | Phase IIb		
monotherapy	**AZD0780 (oPCSK9)** | Phase IIb		
novel combinations		**zibotentan (ETA) + dapa (oSGLT2i)** | Phase III	
novel combinations	**AZD5004 (oGLP1) + dapa (oSGLT2i)**		
novel combinations	**balcinrenone (MRM) + dapa (oSGLT2i)** | Phase III		**AZD6234 (LAA) + AZD9550 (GLP/GCG)**
novel combinations	**baxdrostat (ASI) + dapa (oSGLT2i)** | Phase III		**AZD5004 (oGLP1) + AZD0780 (oPCSK9)**

approved medicine | NME | novel combination

Advancing next-generation CVRM medicines

Established expertise with key foundational medicines

Leveraging new mechanisms to expand existing CVRM focus

Pursuing novel combinations to target complex conditions and address interconnectedness of disease

Development pipeline includes Phase II and Phase III ongoing or planned trials.
Appendix: Glossary.

BioPharmaceuticals – R&D highlights

Positive Phase III WAYPOINT trial reinforces *Tezspire* first-in-class mechanism of action

Phase III WAYPOINT trial

Tezspire met both co-primary endpoints in chronic rhinosinusitis and nasal polyps

Significant patient burden in patients with nasal polyps

- impact on quality of life
- need for surgery and systemic steroids



Statistically significant, clinically meaningful reduction in:

- ✓ Size of nasal polyps
- ✓ Nasal congestion

7 million patients treated for nasal polyps

3 million with uncontrolled nasal polyps (G8)

Multiple *Tezspire* indication expansion opportunities

DIRECTION
- severe asthma (China)
- primary endpoint met

CROSSING
- eosinophilic esophagitis
- readout >2025

New Phase III
- COPD
- initiating H1 2025

***Tezspire* multi-billion $ opportunity[1]**

1. Peak Year Revenue, non-risk adjusted. Collaboration partners: Amgen (*Tezspire*).

Appendix: Glossary.

Rare Disease

Marc Dunoyer
CHIEF EXECUTIVE OFFICER,
ALEXION



Rare Disease – 9M and Q3 2024

Total Revenue +14% in 9M 2024 driven by continued neurology growth

Rare Disease

9M 2024 $6.4bn, +14%



Q3 2024: key dynamics

C5 Franchise: sustainable, durable growth

- ***Ultomiris*** +35%, driven by demand growth in neurology indications (gMG, NMOSD)
- ***Soliris*** (18%), continued conversion to *Ultomiris*, partly offset by growth in Emerging Markets

Beyond Complement: market expansion and increased demand

- ***Strensiq*** +21% and ***Koselugo*** +39%, driven by continued global demand

All growth rates at CER.
1. Includes *Kanuma* and *Koselugo*.
Collaboration partner: Merck & Co., Inc. (*Koselugo*).
Appendix: Glossary.

Rare Disease – R&D highlights

Expanding the potential of *Koselugo* to adult patients with NF1-PN

NF1-PN
a progressive, genetic condition

- characterised by benign tumours that develop on nerve sheaths
- leads to disfigurement, motor dysfunction and pain

US	EU5	JP
68K	64K	22K



20% paediatric <18 years old

80% adults ≥18 years

Phase III KOMET trial[1]
ORR improvement in NF1-PN adult patients



Primary endpoint met:

- statistically significant, clinically meaningful tumour volume reduction
- encouraging effect across pain severities
- low discontinuation rates
- rapid efficacy onset

KOMET has the potential to address the high unmet need in adult patients with NF1-PN

Epidemiology data refers to diagnosed patients, adult and paediatric splits use both external (IQVIA) and internal sources and estimates.
1. KOMET trial allowed cross over to *Koselugo* before 12 cycles. 1 cycle = 28 days.
Collaboration partner: Merck & Co., Inc. (*Koselugo*).
Appendix: Glossary.

CEO Closing Remarks

Pascal Soriot
CHIEF EXECUTIVE OFFICER



AstraZeneca – catalyst rich path through 2025, with potential to unlock significant value through 2030 and beyond

Indication expansion

- ***Enhertu*** – HER2+ eBC, mBC
- ***Imfinzi*** – multiple bladder trials
- ***Fasenra*** – COPD
- ***Truqap*** – d*PTEN* HSPC

Key NME[1] opportunities

- baxdrostat – **BaxHTN** – uHTN
- camizestrant – **SERENA-6** – mBC
- Dato-DXd – NSCLC and TNBC
- eneboparatide – **CALYPSO** – HP

Disruptive technologies

- Cell therapy and TCEs Phase I/II
- In-house ADC Phase I/II
- IO bispecifics Phase I/II
- Weight management Phase I/II

Pipeline momentum supports ambition to achieve $80bn in Total Revenue by 2030

1. NME defined as new molecular entities that are not currently approved medicines. Collaboration partners: Daiichi Sankyo (*Enhertu* and Dato-DXd); Amgen (*Tezspire*).
Appendix: Glossary.

On track to deliver on strategic ambitions

Ambition to deliver **$80bn in Total Revenue by 2030**[1]

On track to deliver **mid-30s% Core operating margin by 2026**

Beyond 2026, Core operating margin will be influenced by portfolio evolution and the Company will target at least mid-30s%

Ambition to deliver **at least 20 NMEs by 2030**

Delivered 6 NMEs to date[2]

1. 2030 Total Revenue ambition at CER, risk adjusted and not dependent upon future M&A. 2. NMEs approved since November 2023 (*Imjudo, Truqap, Voydeya, Wainua, Beyfortus, Airsupra*).
Appendix: Glossary.

Q&A Session

Pascal Soriot
EXECUTIVE DIRECTOR &
CHIEF EXECUTIVE OFFICER

Aradhana Sarin
EXECUTIVE DIRECTOR &
CHIEF FINANCIAL OFFICER

Marc Dunoyer
CHIEF EXECUTIVE OFFICER,
ALEXION

Susan Galbraith
EXECUTIVE VICE PRESIDENT,
ONCOLOGY R&D

Dave Fredrickson
EXECUTIVE VICE PRESIDENT,
ONCOLOGY BUSINESS

Sharon Barr
EXECUTIVE VICE PRESIDENT,
BIOPHARMACEUTICALS R&D

Ruud Dobber
EXECUTIVE VICE PRESIDENT,
BIOPHARMACEUTICALS
BUSINESS

Iskra Reic
EXECUTIVE VICE PRESIDENT,
VACCINES AND IMMUNE
THERAPIES

Appendix & Glossary

- Glossary
- Oncology tumour maps
- Key medicines performance by therapy area



Glossary – abbreviations

ADC	antibody drug conjugate
API	active pharmaceutical ingredient
ASCO	American society of clinical oncology
ASH	American Society of Haematology
ATTR-PN	transthyretin amyloid polyneuropathy
bn	billions
BTD	break through designation
BTKi	Bruton's tyrosine kinase
C5	complement component 5
CER	Constant exchange rates
CFO	cash flow from operating activities
cis	cisplatin
CKD	chronic kidney disease
CN	China
CRwNP	chronic rhinosinusitis with nasal polyps
CTLA-4	cytotoxic T-lymphocyte associated protein 4
CTx	chemotherapy
CVRM	Cardiovascular, renal and metabolism
dPTEN	phosphatase and tensin homolog deficient
EBITDA	Earnings before interest, tax, depreciation and amortisation
*EGFR*m	epidermal growth factor receptor mutant
EHA	European Haematology Association
EM	Emerging Markets
EPS	Earnings per share
ERoW	Established rest of world
ESMO	European society for medical oncology
ET	endocrine therapy
EU5	France, Germany, Italy, Spain, and UK
FDC	fixed dose combination
FX	Foreign exchange
GC	gastric cancer
GEJC	gastroesophageal junction cancer
gem	gemcitabine
Gluc	glucagon
gMG	generalised myasthenia gravis
HCC	Hepatocellular carcinoma
HER2+	human epidermal growth factor receptor 2 positive
HER2-low	human epidermal growth factor receptor 2 low
HR+	hormone receptor positive
HTN	hypertension
ICS	inhaled corticosteroid
IL5	Interleukin 5
IO	Immuno-oncology
JP	Japan
K+	Potassium
LA	long-acting
LDL-C	low-density lipoprotein cholesterol
m	millions
mBC	Metastatic breast cancer
MCL	mantle cell lymphoma
MIBC	muscle invasive bladder cancer
MRM	mineralocorticoid receptor modulator
n/m	Not meaningful
NF1-PN	neurofibromatosis type 1-plexiform neurofibromas
NME	new molecular entity
NMIBC	non-muscle invasive bladder cancer
NMOSD	Neuromyelitis optica spectrum disorder
NSCLC	Non-small cell lung cancer
ODD	orphan drug designation
PS	Product Sales
oGLP1	oral glucagon-like receptor peptide 1
OOI	other operating income
oPCSK9	oral protein convertase subtilisin/kexin type 9
OS	overall survival
PARPi	poly-ADP ribose polymerase inhibitor
PD1	programmed cell death protein 1
PD-L1	programmed cell death ligand 1
PTH	parathyroid hormone
QCS	quantitative continuous scoring
R&D	research and development
R&I	Respiratory and immunology
SABA	short acting beta agonist
SCLC	small cell lung cancer
SG&A	sales, general and administrative
SGLT2i	sodium/glucose cotransporter 2 inhibitor
SoC	standard of care
Stg I/II/III	Stage 1/2/3
TIGIT	T-cell immunoreceptor with immunoglobulin and ITIM domains
TIM-3	T-cell immunoglobulin and mucin domain-containing protein
TKI	tyrosine kinase inhibitor
TNBC	triple negative breast cancer
u/r	unresectable / resectable
UACR	urinary albumin/creatinine ratio
WCLC	World conference on lung cancer
V&I	Vaccines and Immune Therapies

AstraZeneca in Lung Cancer

Ambition for >50% of lung cancer patients to be eligible for AZN medicine by 2030

	resectable	unresectable		metastatic	
	Stg. I-III	Stg. I-II	Stg. III	1L	2L+
Est. epi (G7)	~200K	~30K	~70K	~350K	~290K
IO sensitive c.70%	*Imfinzi* **AEGEAN**	*SBRT → Imfinzi / Tagrisso* **PACIFIC-4**	CRT → *Imfinzi* **PACIFIC**	*Imfinzi + Imjudo* + CTx **POSEIDON**	*Imfinzi* + ceralasertib **LATIFY**
	volrustomig + CTx *Imfinzi* + Dato-DXd + plat **NEOCOAST-2**		*Imfinzi* combos **PACIFIC-8, -9** improvements across PD-L1 spectrum	Dato-DXd + IO ± platinum **TROPION-Lung08/TROPION-Lung07/AVANZAR**	Dato-DXd **TROPION-Lung01**
	rilvegostomig ± Dato-DXd **TROPION-Lung12**			rilvegostomig ± Dato-DXd **TROPION-Lung10**	AZD9592 (EGFR/cMET ADC) **EGRET**
				Enhertu + IO + CTx **DESTINY-Lung03**	
				volrustomig + CTx **eVOLVE-Lung02**	sabestomig (PD-1/TIM3)
*EGFR*m c.16%	*Tagrisso* **ADAURA**		CRT → *Tagrisso* **LAURA**	*Tagrisso* **FLAURA**	savolitinib + *Tagrisso* **SAFFRON/SAVANNAH**
	Tagrisso **neoADAURA**			*Tagrisso + CTx* **FLAURA-2**	Dato-DXd +/- *Tagrisso* **TROPION-Lung15/ 01**
				Dato-DXd + *Tagrisso* **TROPION-Lung14**	AZD9592 (EGFR/cMET ADC) **EGRET**
Other tumour drivers c.12%			CRT → *Imfinzi* **PACIFIC**		
*HER2*m c.2%				*Enhertu* **DESTINY-Lung04**	*Enhertu* **DESTINY-Lung02**

established SoC

Leading the future of lung cancer treatment

- Establishing *Tagrisso* as backbone TKI in *EGFR*m
- *Imfinzi* leading IO in unresectable
- Advancing best-in-class ADCs to replace systemic chemotherapy
- Delivering next-wave bispecifics to improve on PD1/PD-L1
- Developing novel combinations, including IO + ADCs
- Investing behind new technologies and platforms, including cell therapy and testing/screening

Collaboration partners: Daiichi Sankyo (*Enhertu*, Dato-DXd), Compugen (rilvegostomig).
Appendix: Glossary.

AstraZeneca in Breast Cancer

Ambition to eliminate breast cancer as a cause of death

	Early			Metastatic		
established SoC	Neoadjuvant	Adjuvant	1st line	2nd line	3rd line	4th line +
Est. epi (G7)	540k		125k	90k	65k	55k
HER2-positive 15-20%	*Enhertu* ± THP **DESTINY-Breast11**	NST→ residual disease → *Enhertu* **DESTINY-Breast05**	*Enhertu* ± pertuzumab **DESTINY-Breast09**	*Enhertu* **DESTINY-Breast03**	*Enhertu* **DESTINY-Breast02**	
HR-positive 65-75%	Low risk: Good outcomes with current SoC	CTx → camizestrant (± CDK4/6i) **CAMBRIA-2** CTx → AI (± CDK4/6i) 2-5 yrs → camizestrant **CAMBRIA-1**	camizestrant + CDK4/6i **SERENA-4** AI + CDK4/6i → camizestrant + CDK4/6i **SERENA-6** *ESR1*m 35% *Truqap* + *Faslodex* + CDK4/6i **CAPItello292** saruparib + camizestrant **EvoPAR-Breast01** tBRCAm, *PALB2*m 9%	*Truqap* + *Faslodex* **CAPItello291** *PIK3CA, AKT1, PTEN* alt.40% *Enhertu* **DESTINY-Breast06** HER2-low (1+, 2+) 60% HER2-ultralow (0-1+) 25%	Dato-DXd **TROPION-Breast01** *Enhertu* **DESTINY-Breast04** HER2-low (1+, 2+) 60%	
TNBC 10-15%	Dato-DXd + *Imfinzi* **TROPION-Breast04**	NST → residual disease → Dato-DXd ± *Imfinzi* **TROPION-Breast03**	*Truqap* + paclitaxel **CAPItello290** PD-L1+ 40%: Dato-DXd + *Imfinzi* **TROPION-Breast05** PD-L1- 60%: Dato-DXd **TROPION-Breast02**	HER2-low (1+, 2+) 35%		
gBRCAm *5% of HR-positive 15% of TNBC*		CTx → *Lynparza* **OlympiA**	*Lynparza* **OlympiAD**			

RECURRENCE

All numbers are approximate. Illustrative settings and populations, not to scale.
Collaboration partners: Daiichi Sankyo (*Enhertu*, Dato-DXd), Merck & Co., Inc. (*Lynparza*).
Appendix: Glossary.

Oncology

Tagrisso

15% growth at CER to $4,877m in 9M 2024



	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024
EM	406	356	444	408	409	360	488	432	446
ERoW	203	206	202	218	198	163	182	191	186
Europe	268	245	257	284	281	299	302	327	328
US	521	535	521	581	577	597	623	658	714

Lynparza

10% growth at CER to $2,228m in 9M 2024



	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024
EM	117	130	137	142	131	133	167	153	155
ERoW	64	66	68	77	71	65	59	66	62
Europe	239	267	178	187	178	436	191	206	214
US	314	331	268	311	322	352	288	319	347

Due to rounding, the sum of a number of dollar values and percentages may not agree to totals.
Collaboration partner: Merck & Co., Inc. (*Lynparza*).
Appendix: Glossary.

Oncology

Imfinzi

22% growth at CER to $3,463m in 9M 2024



	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024
EM	90	63	81	101	86	87	129	117	120
ERoW	99	97	129	201	207	213	170	183	167
Europe	135	142	162	171	203	207	232	227	236
US	413	437	491	540	570	570	582	620	680

Imjudo

32% growth at CER to $208m in 9M 2024



	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024
EM	0	0	0	1	1	3	4	4	4
ERoW	0	0	4	22	14	12	11	13	12
Europe	0	0	1	5	5	5	8	8	10
US	0	13	32	36	40	38	39	49	46

Due to rounding, the sum of a number of dollar values and percentages may not agree to totals.
Appendix: Glossary.

Oncology

Calquence

27% growth at CER to $2,321m in 9M 2024



	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024
EM	12	17	18	24	28	29	39	36	41
ERoW	18	20	22	27	30	28	32	33	33
Europe	79	86	108	117	128	140	153	167	169
US	457	465	384	485	468	478	494	554	570

Enhertu

60% growth at CER to $1,442m in 9M 2024



	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024
EM	25	29	38	69	72	74	112	112	128
ERoW	2	3	3	5	9	15	13	19	16
Europe	31	33	55	70	79	91	134	129	136
US	124	151	161	178	179	184	202	212	229

Due to rounding, the sum of a number of dollar values and percentages may not agree to totals.
Collaboration partner: Daiichi Sankyo (*Enhertu*).
Appendix: Glossary.

BioPharmaceuticals: Cardiovascular, Renal & Metabolism

Farxiga

34% growth at CER to $5,779m in 9M 2024



	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024
EM	410	441	498	578	579	559	711	763	750
ERoW	84	72	138	136	105	73	152	108	111
Europe	329	342	393	456	506	525	553	680	670
US	279	323	296	339	366	451	475	394	411

Brilinta

1% growth at CER to $992m in 9M 2024



	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024
EM	76	64	82	79	64	61	88	78	66
ERoW	10	8	6	6	6	6	5	4	5
Europe	65	67	67	68	68	68	67	69	67
US	187	206	179	178	193	194	163	191	189

Lokelma

34% growth at CER to $392m in 9M 2024



	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024
EM	9	6	11	13	13	13	21	21	26
ERoW	17	18	20	24	22	24	23	28	26
Europe	8	9	11	14	16	17	18	23	25
US	45	48	56	49	51	58	52	64	66

Due to rounding, the sum of a number of dollar values and percentages may not agree to totals.
Appendix: Glossary.

BioPharmaceuticals: Respiratory & Immunology

Fasenra

8% growth at CER to $1,218m in 9M 2024



	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024
EM	12	13	14	14	19	16	22	19	27
ERoW	35	35	35	36	35	36	33	37	36
Europe	77	76	88	89	86	93	93	99	102
US	229	257	201	267	249	275	210	268	271

Breztri

53% growth at CER to $721m in 9M 2024



	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024
EM	28	21	38	43	42	38	70	61	68
ERoW	9	9	10	15	12	15	14	19	19
Europe	8	11	15	21	19	26	30	35	37
US	58	75	81	84	98	120	105	120	142

Tezspire

>2x growth at CER to $471m in 9M 2024



	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024
EM	0	0	0	0	0	1	2	3	3
ERoW	0	2	4	8	10	14	14	19	22
Europe	0	2	7	11	11	17	27	35	43
US	26	37	43	62	74	83	77	104	123

Due to rounding, the sum of a number of dollar values and percentages may not agree to totals.
Collaboration partners: Amgen (*Tezspire*).
Appendix: Glossary.

BioPharmaceuticals: Respiratory & Immunology

Symbicort

22% growth at CER to $2,195m in 9M 2024



	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024
EM	169	133	229	177	195	153	253	197	203
ERoW	91	95	79	86	81	88	75	83	83
Europe	133	137	147	137	123	142	142	143	130
US	237	255	233	200	156	137	299	299	289

Pulmicort

9% growth at CER to $517m in 9M 2024



	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024
EM	103	123	182	90	119	183	191	126	110
ERoW	12	12	9	11	11	12	8	9	9
Europe	14	19	20	16	13	19	20	17	14
US	16	12	10	7	5	5	5	3	5

Due to rounding, the sum of a number of dollar values and percentages may not agree to totals.
Appendix: Glossary.

Rare Disease

Ultomiris

35% growth at CER to $2,835m in 9M 2024



	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024
EM	4	4	13	17	17	24	32	35	26
ERoW	77	90	98	110	131	138	143	152	170
Europe	122	134	159	152	184	173	202	209	238
US	315	365	381	434	445	490	482	550	597

Soliris

11% decrease at CER to $2,045m in 9M 2024



	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024
EM	84	83	115	99	124	86	125	129	110
ERoW	104	91	88	86	74	68	61	55	48
Europe	190	179	183	184	163	140	142	118	86
US	523	491	448	445	420	421	411	398	362

Strensiq

19% growth at CER to $996m in 9M 2024



	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024
EM	8	10	15	9	5	11	21	10	8
ERoW	19	19	21	22	21	22	22	23	24
Europe	18	19	21	21	22	25	24	24	25
US	192	224	205	248	237	247	246	283	286

Due to rounding, the sum of a number of dollar values and percentages may not agree to totals.
Q3 2021 Total Revenue shows the numbers reported by AstraZeneca following the acquisition of Alexion, which completed on 21 July 2021.
Appendix: Glossary.